Stay Informed While Earning Sleep CME Credits
Sleep is an essential component of health and wellness; yet, many people experience disruptions in their sleep-wake cycle that are severe enough to impair physiological and psychosocial functioning. Disorders of the sleep-wake cycle, such as obstructive sleep apnea, narcolepsy and hypersomnia, as well as associated syndromes such as cataplexy and excessive daytime sleepiness, represent significant health problems with short- and long-term consequences. Sleep disorders have been associated with metabolic effects, changes in circadian rhythms, proinflammatory responses, and psychiatric, neurologic, pulmonary, and cardiac conditions, as well as decrements in neurocognitive domains. Likewise, sleep disorders can negatively impact work performance and attendance, and may contribute to increased injuries and accidents, creating a significant economic burden, as well as increased health care utilization and more frequent and longer hospitalizations.
Given the significant impact of sleep disorders, the identification and implementation of safe, effective therapies is paramount. The CME Outfitters Sleep Disorders Hub is designed to provide clinicians with the latest clinical practice guidelines, diagnostic strategies and tools, and scientific updates on current and emerging therapies to optimize the management of sleep disorders. In addition, the Sleep Disorders Hub also provides patient education tools to empower patients to make informed decisions about their care.
|Join Drs. Bogan, Thorpy, and Weaver for an OnDemand symposium as they discuss evidence-based strategies to reduce EDS and cataplexy, among other symptoms, and restore quality of life and functioning in patients with narcolepsy.|
|Join expert faculty in this OnDemand webcast as they discuss effective tools and strategies to improve the accurate and early detection of narcolepsy, as well as the latest evidence on optimal treatment strategies to achieve sustained benefits by improving clinical outcomes and facilitating adherence.|
|This CME Outfitters OnDemand Webcast will feature expert faculty detailing the functional and clinical impact of IH, best practices and the latest tools for an accurate diagnosis, and the efficacy and safety of novel therapies and how they address the unmet needs of people with IH.|
|This CME Outfitters virtual symposium will take place during the AASM SLEEP 2021 virtual conference. Expert faculty will discuss the spectrum of EDS across the subtypes of narcolepsy, strategies to apply data from recent clinical trials to treatment decision-making, and the impact of emerging agents for the management of EDS in patients with IH.|
|This CMEO Journal Club activity is the first in a three-part series that focuses on the presentation of EDS and evidence-based measures to assess its impact on QoL so that clinicians might better educate patients on the significance of detecting and treating EDS.|
|In this second installment of a 3-part journal club series on making sense of the latest clinical data on EDS in obstructive sleep apnea (OSA) and narcolepsy, featuring expert faculty discussing the factors to consider when making treatment selections for patients and how best to personalize treatment strategies, including which patients would be ideal for JZP-258, transitioning patients from one therapy to another, and dosing considerations.|
|The final installment of this 3-part journal club series hosted by CME Outfitters highlights the latest clinical evidence on novel therapies for EDS in obstructive sleep apnea (OSA) and narcolepsy and how to incorporate this evidence into optimal treatment planning to reduce the burden of EDS.|
|Join Drs. Richard Bogan and Terri Weaver as they discuss case 1 of this 3-part CMEO BriefCase series and provide insight into the extensive impact of OSA-related EDS on psychosocial functioning and HRQoL to promote the need for early intervention.|
|Join Drs. Richard Bogan and Paula Schweitzer as they discuss case 2 of this 3-part CMEO BriefCase series and provide guidance on the nuances of personalizing treatment selection and strategies to monitor treatment effectiveness to provide safe, effective, long-term care.|
|This CME Outfitters podcast will focus on considering individual patient characteristics along with updated clinical parameters and newly approved narcolepsy medications so that clinicians can identify and implement effective treatment to achieve long-term benefits by improving clinical outcomes and therefore patient QOL.|
|Join Drs. Thorpy and Emsellem in this first installment of a CMEOCast series on EDS in narcolepsy as they inform clinicians not only of the extensive burden imposed by narcolepsy but also diagnostic strategies to facilitate early detection and the implementation of effective treatment.|
|This CMEOCast podcast focuses on developing personalized, effective strategies to reduce EDS in patients with OSA or narcolepsy, including an overview of data on incorporating the use of safer, lower sodium alternatives to mitigate EDS without imposing cardiovascular burden.|
|This CME Outfitters Snack will help clinicians navigate scientific updates on the safety and efficacy of emerging therapies for IH presented at the Sleep 2021 Annual Meeting and offer insights into best practices for applying those updates to clinical decision-making.|
|This CME Outfitters Snack features expert faculty discussing the latest clinical evidence on the cardiovascular burden of narcolepsy and the need to consider cardiovascular comorbidities and other risk factors to inform treatment planning for patients with narcolepsy.|
|This CME Outfitters Snack will examine the latest clinical evidence from the Sleep 2021 Annual Meeting on the safety, efficacy, and dosing of novel treatment strategies for IH, with and without long sleep time.|
This video provides an overview of narcolepsy and its symptoms. Also included are patient resources promoting advocacy, education, and valuable tools to personalize treatment plans through shared decision making.
In this video, Dr. Bogan uses an augmented reality animation to describe the extensive impact EDS can have on both medical and psychiatric conditions.
In this video, Dr. Bogan uses an augmented reality animation to examine the regions of the brain that promote sleep and wakefulness, and the neurotransmitters involved.
In this video, Dr. Bogan uses an augmented reality animation to describe the interaction of traditional stimulants such as amphetamines on the sleep-wake cycle. This video will also explain the differences between non-selective stimulants and selective stimulants such as modafinil and armodafinil.
In this video, Dr. Bogan uses an augmented reality animation to explore how through the inhibition of dopamine and norepinephrine reuptake, solriamfetol produces its potent wake-promoting effect and improvement in the symptoms of EDS.
In this video, Dr. Bogan uses an augmented reality animation to explain how pitolisant increases levels of histamine in the brain to decrease symptoms of EDS and improve wakefulness, vigilance, attention, and memory.
- Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline
- Use of Actigraphy for the Evaluation of Sleep Disorders and Circadian Rhythm Sleep-Wake Disorders: An American Academy of Sleep Medicine Clinical Practice Guideline
- Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline
- Quality Measures for the Care of Patients with Narcolepsy
- Quality Measures for the Care of Adult Patients with Obstructive Sleep Apnea
- Practice Parameters for the Treatment of Narcolepsy and other Hypersomnias of Central Origin
- Practice Parameters for the Indications for Polysomnography and Related Procedures: An Update for 2005
- Practice Parameters for Clinical Use of the Multiple Sleep Latency Test and the Maintenance of Wakefulness Test
- Evaluation, Management and Long-Term Care of OSA in Adults
- Clinical Guideline for the Evaluation, Management and Long-term Care of Obstructive Sleep Apnea in Adults
- One Week Sleep Diary Sample
- Epworth Sleepiness Scale
- Two Week Sleep Diary
- Swiss Narcolepsy Scale
- Idiopathic Hypersomnia Severity Scale (IHSS)
- Sleep Diary Sample
- Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD)
- Narcolepsy Severity Scale (NSS)
Digital Health Tools
- American Academy of Sleep Medicine (AASM) Sleep TM app, a mobile app that directly connects patients to sleep medicine professionals and accredited sleep centers through the AASM SleepTM telemedicine system. The app provides patients convenient access to sleep medicine services on their mobile devices. – Click Here
- Sleep Tuner, FDA-registered sleep sensor, worn on the forehead, to measure blood oxygenation, heart rate, sleep position, and stopped breathing events. It is designed to offer the accuracy of medical sleep studies without the cost or inconvenience. – Click Here
- ResApp, uses a smartphone to detect sleep apnea by sound, delivering a highly-scalable, accurate, and easy-to-use screening test. It uses a machine-learning algorithm to detect the severity of sleep apnea by the sound of a person’s breathing and snoring. A user can put the smartphone next to their bed and it will record their sleeping. – Click Here
- DeepHeart, a deep neural network technology that can detect hypertension and sleep apnea. – Click Here
- Healthy Sleep Duration Poster
- Stop the Snore Infographic
- Little Sleep, Big Costs Infographic
- Sleep Apnea Hurts Hearts
- How Too Much Sodium Affects Your Health
- Sodium Myths and Facts for Kids
- Sleep Education (from the American Academy of Sleep Medicine): http://www.sleepeducation.org
- National Healthy Sleep Awareness Project (from the American Academy of Sleep Medicine): http://www.sleepeducation.org/healthysleep
- National Sleep Foundation: https://www.sleepfoundation.org
- American Sleep Association: https://www.sleepassociation.org
- National Heart, Lung, and Blood Institute-National Institutes of Health: https://www.nhlbi.nih.gov/health-pro/resources/sleep
- Thorpy MJ, Shapiro C, Mayer G, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85(3):359-370. Download PDF
- Abad VC. An evaluation of sodium oxybate as a treatment option for narcolepsy. Expert Opin Pharmacother. 2019;20(10):1189-1199. Available at https://www.ncbi.nlm.nih.gov/pubmed/31136215.
- Black J, Swick T, Bogan R, et al. Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy. Sleep Med. 2016;24:57-62. Download PDF
- Schweitzer PK, Rosenberg R, Zammit GK, et al. Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial. Am J Respir Crit Care Med. 2019;199(11):1421-1431. Available at https://www.ncbi.nlm.nih.gov/pubmed/30521757.
- Martinez-Garcia MA, Campos-Rodriguez F, Barbé F, et al. Precision medicine in obstructive sleep apnoea. Lancet Respir Med. 2019 May;7(5):456-464. Available at https://www.ncbi.nlm.nih.gov/pubmed/30987857.
- Inoue Y, Miki M, Tabata T. Findings of the Maintenance of Wakefulness Test and its relationship with response to modafinil therapy for residual excessive daytime sleepiness in obstructive sleep apnea patients adequately treated with nasal continuous positive airway pressure. Sleep Med. 2016;27-28:45-48. Available at https://www.ncbi.nlm.nih.gov/pubmed/27938918.
- Scheer D, Schwartz SW, Parr M, et al. Prevalence and Incidence of Narcolepsy in a U.S. Health Care Claims Database, 2008-2010. Sleep. 2019. Epub ahead of print]. Available at https://www.ncbi.nlm.nih.gov/pubmed/31004158.
- Thorpy MJ, Hiller G. The Medical and Economic Burden of Narcolepsy: Implications for Managed Care. Am Health Drug Benefits. 2017;10(5):233-241. – Download PDF
- Hein M, Lanquart JP, Loas G, et al. Prevalence and risk factors of excessive daytime sleepiness in major depression: A study with 703 individuals referred for polysomnography. J Affect Disord. 2019 Jan 15;243:23-32. Available at https://www.ncbi.nlm.nih.gov/pubmed/30223136.
- Kallweit U, Bassetti CL. Pharmacological management of narcolepsy with and without cataplexy. Expert Opin Pharmacother. 2017;18(8):809-817. Available at https://www.ncbi.nlm.nih.gov/pubmed/28443381.
- Mayer G, Piazzi G, Iranzo A, et al. Long-term compliance, safety, and tolerability of sodium oxybate treatment in patients with narcolepsy type 1: a post-authorization, noninterventional surveillance study. Sleep. 2018;41(9). – Download PDF
- Szabo ST, Thorpy MJ, Mayer G, et al. Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy. Sleep Med Rev. 2019;43:23-36. – Download PDF
- Gentina T, Bailly S, Jounieaux F, et al. Marital quality, partner’s engagement and continuous positive airway pressure adherence in obstructive sleep apnea. Sleep Med. 2019;55:56-61. Available at https://www.ncbi.nlm.nih.gov/pubmed/30771736.
- Schöbel C, Knorre S, Glos M, et al. Improved follow-up by peripheral arterial tonometry in CPAP-treated patients with obstructive sleep apnea and persistent excessive daytime sleepiness. Sleep Breath. 2018 Dec;22(4):1153-1160. Available at https://www.ncbi.nlm.nih.gov/pubmed/29956104.
- Avellar AB, Carvalho LB, Prado GF, et al. Pharmacotherapy for residual excessive sleepiness and cognition in CPAP-treated patients with obstructive sleep apnea syndrome: A systematic review and meta-analysis. Sleep Med Rev. 2016;30:97-107. Available at https://www.ncbi.nlm.nih.gov/pubmed/27865102.
- Gasa M, Tamisier R, Launois SH, et al. Residual sleepiness in sleep apnea patients treated by continuous positive airway pressure. J Sleep Res. 2013;22(4):389-397. – Download PDF
- Inoue Y, Takasaki Y, Yamashiro Y. Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated Japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study. J Clin Sleep Med. 2013;9(8):751-757. – Download PDF
- Sukhal S, Khalid M, Tulaimat A. Effect of Wakefulness-Promoting Agents on Sleepiness in Patients with Sleep Apnea Treated with CPAP: A Meta-Analysis. J Clin Sleep Med. 2015;11(10):1179-1186. – Download PDF